# AWAK Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/awak-technologies

- Industry: Medical Devices & Equipment
- Headquarters: Singapore, Singapore
- Website: www.awak.com
- Total disclosed funding: $43M
- Latest round: Series B (Sep 19, 2023)
- Investors on record: 7

## About

AWAK Technologies Inc., based in Singapore, develops innovative solutions for kidney care, focusing on enhancing patient outcomes through advanced dialysis technologies.Founded in 2007 by Kok Neo, AWAK Technologies Inc. specializes in kidney care technology. The company is headquartered in Singapore and has pursued multiple funding rounds to support its operations and product development. The most recent funding took place in September 2023, where the company raised USD 2.50 mn in a Series B round, co-led by Lion X Ventures and Vickers Venture Partners, with additional investments from Advanced MedTech Holdings and Eckuity. To date, AWAK Technologies has participated in 4 deals, accumulating a total of USD 2.50 mn in funding, with a current valuation of USD 141.89 mn.AWAK Technologies offers a range of kidney care solutions that address the challenges of chronic kidney disease. Key products include the Viva Komfort for point-of-care dialysis fluid generation and infection management, the ultraportable Viva Kompact for on-the-go dialysis, and the Viva Konnect, which integrates digital and AI technology for remote patient monitoring. These innovations are designed primarily for healthcare facilities and patients across North America, Europe, and parts of Asia, targeting the global public health issue of kidney disease affecting one in ten individuals.In the most recent fiscal year of 2019, AWAK Technologies reported zero revenue, with an EBITDA loss of USD 13,848,388.30 for the year 2023. The company's revenue model is based on direct sales and partnerships with healthcare institutions, facilitating transactions through procurement agreements for their products such as Viva Komfort and Viva Kompact.In September 2023, AWAK Technologies Inc. successfully raised USD 2.50 mn in Series B funding, which will be allocated to support ongoing clinical trials and facilitate the company's entry into the US market. The company is committed to developing new products to enhance kidney care and is actively planning to expand its reach into new markets, particularly focusing on the US healthcare sector by the end of 2024.

## Funding rounds

- Series B, Sep 19, 2023, $2.5M — Vickers Venture Partners, Advanced MedTech Holdings, Eckuity Capital, Lion X Ventures
- Series B, Dec 10, 2019, $41M — Vickers Venture Partners, Baxter International, Inc., V V Pentafond Pte. Ltd., SEEDS Capital, Advanced MedTech Holdings

## Investors

- Vickers Venture Partners (https://capitalatlas.ai/funds/vickers-venture-partners) — Series B
- Baxter International, Inc. — Series B
- V V Pentafond Pte. Ltd. — Series B
- SEEDS Capital (https://capitalatlas.ai/funds/seeds-capital) — Series B
- Advanced MedTech Holdings — Series B
- Eckuity Capital (https://capitalatlas.ai/funds/eckuity-capital) — Series B
- Lion X Ventures — Series B